Erratum to: Hepatol Int DOI 10.1007/s12072-016-9761-2
In the original publication, some entries in Table 2 are incorrect. The corresponding text under the subsection, Phase 3 studies, paragraph 6 in page 7 is also incorrectly published as GT subtype SVR12 rates were 60% for GT1a, 40% for GT1b, 13% for GT4, and 1% for GT6 infected patients. It should read as (GT1a 94%, GT1b 95%, GT4 96%, and GT6 100%).
The corrected version of Table 2 is provided below.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s12072-016-9761-2.
Rights and permissions
About this article
Cite this article
Papudesu, C., Kottilil, S. & Bagchi, S. Erratum to: Elbasvir/grazoprevir for treatment of chronic hepatitis C virus infection. Hepatol Int 11, 315–316 (2017). https://doi.org/10.1007/s12072-016-9781-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12072-016-9781-y